We were inspired by the recent article by van Erpecum and Dalekos [1], which proposed new horizons in the diagnosis and management of patients with metabolic dysfunction-associated steatotic liver disease (MASLD). In response, we evaluated the newly introduced nomenclature for steatotic liver disease (SLD) [2] and its implications in an elderly cohort in Beijing.
